Back to search results

Research Study for Heart Failure and Obesity with NNC0487-0111

This research study is looking at how well a new medicine called NNC0487-0111 works compared to a placebo (an inactive substance) in people who have heart failure (when your heart can't pump enough blood) and obesity (excess body weight). The study wants to see if NNC0487-0111 is safe and effective for treating heart failure with preserved or mildly reduced ejection fraction (HFpEF or HFmrEF). You might be able to join if you are 18 or older, have a BMI of 30 or more, and have stable heart failure. If you have Type 2 Diabetes, it must have been diagnosed at least 30 days before screening. The study will measure how long it takes for a heart failure event to happen, like a hospital stay or urgent visit. The study is currently unclear on its recruitment status.

Study design
This is an interventional study with a planned enrollment of 5610 participants. Participants will be randomly assigned to receive either NNC0487-0111 or a placebo.
What's involved
Participants will receive weekly injections of either NNC0487-0111 or placebo under the skin.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 165 weeks (about 3 years and 2 months) to track heart failure events.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07567001

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

Recruiting
PHASE3Ages 18+InterventionalTreatment
Novo Nordisk A/S
~5,610 participants
Updated 2026-08-18 on ClinicalTrials.gov
What's tested:NNC0487-0111Placebo

At a glance

Recruiting sites
530 of 838 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to first occurrence of a composite Heart Failure (HF) endpoint consisting of cardiovascular (CV) death
Measured over From baseline (week 0) to 165 weeks
+1 more outcome measured

Conditions

Obesity
Heart Failure

Explore related trials

Heart FailureObesity

Where it's being run

838 sites across 178 states
Germany46
Poland37
Bulgaria34
California33
Japan31
Turkey (Türkiye)31
Texas27
United Kingdom27

Study leadership

  • Clinical Transparency (dept. 2834) · STUDY_DIRECTOR · Novo Nordisk A/S

Who to contact

Novo Nordisk
[email protected]
(+1) 866-867-7178
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Body Mass Index (BMI) greater than or equal to (\>=) 30 kilograms per square metre (kg/m\^2) at screening.
Diagnosis of HF with New York Heart Association (NYHA) class II-IV and in stable condition at screening, at the discretion of the investigator.

Exclusion

MI, stroke, unstable angina pectoris or worsening HF leading to either hospitalization or intravenous loop diuretics within 30 days prior to the day of screening and until randomization.
HF due to infiltrative cardiomyopathy (e.g., sarcoid, amyloid), arrhythmogenic right ventricular cardiomyopathy, Takutsubo cardiomyopathy, Chagas cardiomyopathy, genetic hypertrophic cardiomyopathy or obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, or uncorrected primary valve disease of moderate or severe degree.
Severe pulmonary disease including primary pulmonary hypertension, chronic pulmonary embolism, or severe chronic obstructive pulmonary disease (COPD) defined as:
requiring home oxygen; or - ongoing oral corticosteroid therapy; or - hospital for COPD Exacerbation within 12 months prior to screening.
Any other condition judged by the investigator to be the cause of HF symptoms (e.g., anaemia, hypothyroidism).
History of type 1 diabetes.
Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or who, at the time of screening, are expected to require treatment within 180 days after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomization. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Glycated haemoglobin (HbA1c) greater than (\>) 10 percent (%) (86 \[millimoles per mole\] mmol/mol) as measured by local or central laboratory at screening.

What this trial measures

  • Time to first occurrence of a composite Heart Failure (HF) endpoint consisting of cardiovascular (CV) deathFrom baseline (week 0) to 165 weeks

    Measured in days.

  • Time to first occurrence of a composite HF endpoint consisting of HF hospitalisation or urgent HF visitFrom baseline (week 0) to 165 weeks

    Measured in days.